Madrid

• Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended
  2023-506657-38-00 5 2019-10-02 Biliary Tract Carcinoma
• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma
• A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY … Ended
  2022-502858-14-00 5 2019-09-05 Hypertrophic cardiomyopathy
• Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended
  2023-503956-29-00 5 2019-08-26 Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient M
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced S … Ended
  2024-513574-21-00 1 2019-08-09 Neoplasms
• The Late Presenter Treatment Optimisation Study (LAPTOP) Ended
  2023-505167-36-00 5 2019-08-05 Patients who present late on during their acquisition of the HIV-1 (Hu
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• Open-label Follow-up Study of Soticlestat in Adults and Children with Developmental Epileptic Encephalopathies Ended
  2022-502801-13-00 4 2019-07-26 Epileptic Encephalopathies: Dravet Syndrome, Lennox Gastaut Syndrome,
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with lo … Ended
  2023-509053-32-00 5 2019-07-17 Locoregional Hepatocellular Carcinoma (HCC)
• Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunoch … Ended
  2023-507498-16-00 9 2019-07-02 Diffuse Large B-Cell Lymphoma (DLBCL)
• Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended
  2022-501439-18-00 5 2019-06-26 NSCLC with squamous or nonsquamous histology
• Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended
  2023-508449-41-00 5 2019-06-26 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
• Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended
  2022-500413-11-00 5 2019-06-17 Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 5 2019-06-12 Multiple myeloma (MM) with at least 2 prior therapies including an imm
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma … Ended
  2024-511316-25-00 3 2019-06-04 Urothelial carcinoma (UC)
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS) Ended
  2023-503898-38-00 5 2019-05-24 Atopic Dermatitis
• A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors Ended
  2024-510984-52-00 1 2019-05-24 Patients with tumors
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• The safety and efficacy of Alpha-1 Antitrypsin (AAT) for the prevention of graft‑versus-host disease (GVHD) in patients receiving hematopoie … Ended
  2024-511164-92-00 10 2019-05-17 Acute Graft versus host disease
• A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended
  2023-509304-16-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)

Showing 3,385–3,408 of 3,550 trials